Establishment of experimental models for Alzheimer's disease research

International Journal of Neuroscience

Volumn 123, Issue 12, 2013, Pages 823-831

  Li, Yunlong ^a,b  

^a KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b KUNMING INSTITUTE OF ZOOLOGY   (China)

Author keywords

AD pathology; Alzheimer's disease (AD); Experimental model

Indexed keywords

ALUMINUM CHLORIDE; AMYLOID; APOMORPHINE; BETA SECRETASE 1; CHOLESTEROL; COPPER; DANTROLENE; DIMEBON; GALACTOSE; GAMMA SECRETASE; GREEN FLUORESCENT PROTEIN; MAGNESIUM; TAU PROTEIN;

ACTIVE IMMUNIZATION; AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTERIOSCLEROSIS; ARTICLE; ASCIDIACEA; BODY SIZE; BRAIN REGION; CHOLESTEROL DIET; CHOLESTEROL INTAKE; COGNITIVE DEFECT; DROSOPHILA MELANOGASTER; EXPERIMENTAL MODEL; HYPERCHOLESTEROLEMIA; IMMUNOTHERAPY; NEMATODE; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PHYLOGENY; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RISK FACTOR; SCANDENTIA; SENESCENCE; SENILE PLAQUE; THERAPY EFFECT; TRANSGENIC MOUSE; ANIMAL; DISEASE MODEL; HUMAN; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS;

EID: 84887927271     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2013.804821     Document Type: Article

References (100)

1. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14:e1-26.
2. Forstl H, Kurz A. Clinical features of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1999;249:288-290.
3. Brookmeyer R, Johnson E, Ziegler-Graham K, et al. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007;3:186-91.
4. Seeman P, Seeman N. Alzheimer's disease: beta-amyloid plaque formation in human brain. Synapse 2011;65:1289-97.
5. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-5.
6. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007;8:663-72.
7. Finch CE, Stanford CB. Meat-adaptive genes and the evolution of slower aging in humans. Q Rev Biol 2004;79:3- 50.
8. Rosen RF, Farberg AS, Gearing M, et al. Tauopathy with paired helical filaments in an aged chimpanzee. J CompNeurol 2008;509:259-70.
9. Bading JR, Yamada S, Mackic JB, et al. Brain clearance of Alzheimer's amyloid-beta40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J Drug Target 2002;10:359-68.
10. Sarasa M, Pesini P. Natural non-transgenic animal models for research in Alzheimer's disease. Curr Alzheimer Res 2009;6:171-8.
11. Janecka JE, Miller W, Pringle TH, et al. Molecular and genomic data identify the closest living relative of primates. Science 2007;318:792-4.
12. Yamashita A, Fuchs E, Taira M, et al. Amyloid beta (Abeta) protein- and amyloid precursor protein (APP)- immunoreactive structures in the brains of aged tree shrews. Curr Aging Sci 2010;3:230-8.
13. Head E, Pop V, Sarsoza F, et al. Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. J Alzheimers Dis 2010;20:637-46.
14. Head E, Pop V, Vasilevko V, et al. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci 2008;28:3555-66.
15. Siwak CT, Tapp PD, Milgram NW. Effect of age and level of cognitive function on spontaneous and exploratory behaviors in the beagle dog. Learn Mem 2001;8:317-25.
16. Siwak CT, Tapp PD, Head E, et al. Chronic antioxidant and mitochondrial cofactor administration improves discrimination learning in aged but not young dogs. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:461-9.
17. Landsberg G. Therapeutic agents for the treatment of cognitive dysfunction syndrome in senior dogs. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:471-9.
18. Siwak CT, Gruet P, Woehrle F, et al. Comparison of the effects of adrafinil, propentofylline, and nicergoline on behavior in aged dogs. Am J Vet Res 2000;61:1410-4.
19. Carrodeguas JA, Rodolosse A, Garza MV, et al. The chick embryo appears as a natural model for research in beta-amyloid precursor protein processing. Neuroscience 2005;134:1285-300.
20. Gerhardsson L, Lundh T, Minthon L, et al. Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2008;25:508-15.
21. Walton JR. A longitudinal study of rats chronically exposed to aluminum at human dietary levels. Neurosci Lett 2007;412:29-33.
22. Luo Y, Niu F, Sun Z, et al. Altered expression of Abeta metabolism-associated molecules from D-galactose/AlCl(3) induced mouse brain. Mech Ageing Dev 2009;130:248-52.
23. Shuchang H, Qiao N, Piye N, et al. Protective effects of gastrodia elata on aluminium-chloride-induced learning impairments and alterations of amino acid neurotransmitter release in adult rats. Restor Neurol Neurosci 2008;26:467-73.
24. He X, Zhong ZM, Che Y. [Locomotor activity and learning and memory abilities in Alzheimer's disease induced by Aluminum in an acid environment in Zebrafish].Dongwuxue Yanjiu 2012;33:231-6.
25. Hua H, Munter L, Harmeier A, et al. Toxicity of Alzheimer's disease-associated Abeta peptide is ameliorated in a Drosophila model by tight control of zinc and copper availability. Biol Chem 2011;392:919-26.
26. Andrasi E, Pali N, Molnar Z, et al. Brain aluminum, magnesium and phosphorus contents of control and Alzheimerdiseased patients. J Alzheimers Dis 2005;7:273-84.
27. Luo Y, Zhang J, Liu N, et al. Copper ions influence the toxicity of beta-amyloid(1-42) in a concentration-dependent manner in a Caenorhabditis elegans model of Alzheimer's disease. Sci China Life Sci 2011;54:527-34.
28. Solomon A, Kivipelto M, Wolozin B, et al. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 2009;28:75-80.
29. Sparks DL,Kuo YM, Roher A, et al. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. Ann N Y Acad Sci 2000;903:335-44.
30. Prasanthi JR, Schrag M, Dasari B, et al. Deferiprone reduces amyloid-beta and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet. J Alzheimers Dis 2012;30:167-82.
31. Cui X, Zuo P, Zhang Q, et al. Chronic systemic D-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: protective effects of R-alpha-lipoic acid. J Neurosci Res 2006;84:647-54.
32. Hua X, Lei M, Zhang Y, et al. Long-term D-galactose injection combined with ovariectomy serves as a new rodent model for Alzheimer's disease. Life Sci 2007;80:1897-905.
33. Sun ZZ, Chen ZB, Jiang H, et al. Alteration of Abeta metabolism-related molecules in predementia induced by AlCl3 and D-galactose. Age (Dordr) 2009;31:277-84.
34. El-Amouri SS, Zhu H, Yu J, et al. Neprilysin protects neurons against Abeta peptide toxicity. Brain Res 2007;1152:191-200.
35. Nitta A, Itoh A, Hasegawa T, et al. beta-Amyloid proteininduced Alzheimer's disease animal model. Neurosci Lett 1994;170:63-6.
36. NobakhtM, Hoseini SM,Mortazavi P, et al. Neuropathological changes in brain cortex and hippocampus in a rat model of Alzheimer's disease. Iran Biomed J 2011;15:51-8.
37. Li W, Wu Y, Min F, et al. A nonhuman primate model of Alzheimer's disease generated by intracranial injection of amyloid-beta42 and thiorphan. Metab Brain Dis 2010;25:277-84.
38. Billings LM, Oddo S, Green KN, et al. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005;45:675-88.
39. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-6.
40. Murrell J, Farlow M, Ghetti B, et al. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991;254:97-9.
41. Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992;1:345-7.
42. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102.
43. Moechars D, Dewachter I, Lorent K, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 1999;274:6483-92.
44. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7.
45. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 2004;24:6144-51.
46. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-9.
47. Van Dam D, De Deyn PP. Animal models in the drug discovery pipeline for Alzheimer's disease. Br J Pharmacol 2011;164:1285-300.
48. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 1997;3:67-72.
49. Chui DH, Tanahashi H, Ozawa K, et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med 1999;5:560-4.
50. Duff K, Eckman C, Zehr C, et al. Increased amyloidbeta42( 43) in brains of mice expressing mutant presenilin 1. Nature 1996;383:710-3.
51. Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998;4:97-100.
52. Borchelt DR, Ratovitski T, van Lare J, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997;19:939-45.
53. Tempier A, He J, Zhu S, et al. Quetiapine modulates conditioned anxiety and alternation behavior in Alzheimer's transgenic mice. Curr Alzheimer Res. 2013 Feb;10(2):199-206.
54. Mei Z, Zhang F, Tao L, et al. Cryptotanshinone, a compound from Salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alpha-secretase in vivo and in vitro. Neurosci Lett 2009;452:90-5.
55. Paris D, Ganey NJ, Laporte V, et al. Reduction of betaamyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 2010;7:17.
56. Oddo S, Caccamo A, Kitazawa M, et al. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease.Neurobiol Aging 2003;24:1063- 70.
57. Perez SE, Nadeem M, Sadleir KR, et al. Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice. Int J Physiol Pathophysiol Pharmacol 2012;4:115-27.
58. Himeno E, Ohyagi Y, Ma L, et al. Apomorphine treatment in Alzheimer mice promoting amyloid-beta degradation. Ann Neurol 2011;69:248-56.
59. Peng J, Liang G, Inan S, et al. Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice. Neurosci Lett 2012;516:274-9.
60. Girard LR, Fiedler TJ, Harris TW, et al. WormBook: the online review of Caenorhabditis elegans biology. Nucleic Acids Res 2007;35:D472-5.
61. Link CD. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A 1995;92:9368-72.
62. Fay DS, Fluet A, Johnson CJ, et al. In vivo aggregation of betaamyloid peptide variants. J Neurochem 1998;71:1616-25.
63. Link CD, Johnson CJ, Fonte V, et al. Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol Aging 2001;22:217-26.
64. Styren SD, Hamilton RL, Styren GC, et al. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem 2000;48:1223-32.
65. Jowett T. Transgenic zebrafish. Methods Mol Biol 1999;97:461-86.
66. Sager JJ, Bai Q, Burton EA. Transgenic zebrafish models of neurodegenerative diseases. Brain Struct Funct 2010;214:285-302.
67. Newman M, Verdile G, Martins RN, et al. Zebrafish as a tool in Alzheimer's disease research. Biochim Biophys Acta 2011;1812:346-52.
68. Newman M, Wilson L, Camp E, et al. A zebrafish melanophore model of amyloid beta toxicity. Zebrafish 2010;7:155-9.
69. Tomasiewicz HG, Flaherty DB, Soria JP, et al. Transgenic zebrafish model of neurodegeneration. J Neurosci Res 2002;70:734-45.
70. Bai Q, Garver JA, Hukriede NA, et al. Generation of a transgenic zebrafish model of Tauopathy using a novel promoter element derived from the zebrafish eno2 gene. Nucleic Acids Res 2007;35:6501-16.
71. Paquet D, Bhat R, Sydow A, et al. A zebrafishmodel of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest 2009;119:1382-95.
72. Jeibmann A, Paulus W. Drosophila melanogaster as a model organism of brain diseases. Int J Mol Sci 2009;10:407-40.
73. Greeve I, Kretzschmar D, Tschape JA, et al. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci 2004;24:3899-906.
74. Finelli A, Kelkar A, Song HJ, et al. A model for studying Alzheimer's Abeta42-induced toxicity in Drosophila melanogaster. Mol Cell Neurosci 2004;26:365-75.
75. Crowther DC, Kinghorn KJ, Miranda E, et al. Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience 2005;132:123-35.
76. Iijima K, Chiang HC, Hearn SA, et al. Abeta42 mutants with different aggregation profiles induce distinct pathologies in Drosophila. PLoS One 2008;3:e1703.
77. Shulman JM, Feany MB. Genetic modifiers of tauopathy in Drosophila. Genetics 2003;165:1233-42.
78. Jackson GR, Wiedau-Pazos M, Sang TK, et al. Human wildtype tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002;34:509-19.
79. Virata MJ, Zeller RW. Ascidians: an invertebrate chordate model to study Alzheimer's disease pathogenesis. Dis Model Mech 2010;3:377-85.
80. Gervais F, Paquette J, Morissette C, et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007;28:537-47.
81. Bharadwaj P, Martins R, Macreadie I. Yeast as a model for studying Alzheimer's disease. FEMS Yeast Res 2010;10:961-9.
82. Zhang H, Komano H, Fuller RS, et al. Proteolytic processing and secretion of human beta-amyloid precursor protein in yeast. Evidence for a yeast secretase activity. J Biol Chem 1994;269:27799-802.
83. Le Brocque D, Henry A, Cappai R, et al. Processing of the Alzheimer's disease amyloid precursor protein in Pichia pastoris: immunodetection of alpha-, beta-, and gamma-secretase products. Biochemistry 1998;37:14958-65.
84. ZhangW, EspinozaD,Hines V, et al. Characterization of betaamyloid peptide precursor processing by the yeast Yap3 and Mkc7 proteases. Biochim Biophys Acta 1997;1359:110-22.
85. Luthi U, Schaerer-Brodbeck C, Tanner S, et al. Human beta-secretase activity in yeast detected by a novel cellular growth selection system. Biochim Biophys Acta 2003;1620: 167-78.
86. Middendorp O, Ortler C, Neumann U, et al. Yeast growth selection system for the identification of cell-active inhibitors of beta-secretase. Biochim Biophys Acta 2004;1674:29-39.
87. Edbauer D, Winkler E, Regula JT, et al. Reconstitution of gamma-secretase activity. Nat Cell Biol 2003;5:486-8.
88. Edbauer D, Kaether C, Steiner H, et al. Co-expression of nicastrin and presenilin rescues a loss of function mutant of APH-1. J Biol Chem 2004;279:37311-15.
89. Futai E, Yagishita S, Ishiura S. Nicastrin is dispensable for gamma-secretase protease activity in the presence of specific presenilin mutations. J Biol Chem 2009;284:13013-22.
90. Steiner H, Pesold B, Haass C. An in vivo assay for the identification of target proteases which cleave membrane-associated substrates. FEBS Lett 1999;463:245-9.
91. Steiner H, Revesz T, Neumann M, et al. A pathogenic presenilin-1 deletion causes abberrant Abeta 42 production in the absence of congophilic amyloid plaques. J Biol Chem 2001;276:7233-9.
92. Hughes SR, Goyal S, Sun JE, et al. Two-hybrid system as a model to study the interaction of beta-amyloid peptide monomers. Proc Natl Acad Sci U S A 1996;93:2065-70.
93. Caine J, Sankovich S, AntonyH, et al. Alzheimer's Abeta fused to green fluorescent protein induces growth stress and a heat shock response. FEMS Yeast Res 2007;7:1230-6.
94. Macreadie I, Lotfi-Miri M, Mohotti S, et al. Validation of folate in a convenient yeast assay suited for identification of inhibitors of Alzheimer's amyloid-beta aggregation. J Alzheimers Dis 2008;15:391-6.
95. Vandebroek T, Vanhelmont T, Terwel D, et al. Identification and isolation of a hyperphosphorylated, conformationally changed intermediate of human protein tau expressed in yeast. Biochemistry 2005;44:11466-75.
96. Vandebroek T, Terwel D, Vanhelmont T, et al. Microtubule binding and clustering of human Tau-4R and Tau- P301L proteins isolated from yeast deficient in orthologues of glycogen synthase kinase-3beta or cdk5. J Biol Chem 2006;281:25388-97.
97. Bharadwaj P, Waddington L, Varghese J, et al. A new method to measure cellular toxicity of non-fibrillar and fibrillar Alzheimer's Abeta using yeast. J Alzheimers Dis 2008;13:147-50.
98. Gotz J, Streffer JR, David D, et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry 2004;9:664-83.
99. Duff K, Suleman F. Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development? Brief Funct Genomic Proteomic 2004;3:47-59.
100. Yamashita A, Fuchs E, Taira M, et al. Somatostatinimmunoreactive senile plaque-like structures in the frontal cortex and nucleus accumbens of aged tree shrews and Japanese macaques. J Med Primatol 2012;41:147-57.